Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Recruiting
National Cancer Institute (NCI)
Phase 2
2015-08-12
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Recruiting
National Cancer Institute (NCI)
Phase 2
2017-07-24
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients
with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have
spread to other places in the body and have come back or do not respond to treatment.
Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth.
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Recruiting
National Cancer Institute (NCI)
Phase 2
2019-09-18
This phase II trial studies the side effects and how well larotrectinib works in treating
patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that
has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking
the TRK enzymes needed for cell growth.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
